Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.76)
# 3,332
Out of 5,072 analysts
60
Total ratings
45.24%
Success rate
-2.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $35.58 | -15.68% | 6 | Oct 21, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $157 → $139 | $109.09 | +27.42% | 10 | Oct 17, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $20 → $24 | $20.83 | +15.22% | 6 | Sep 18, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.18 | -14.89% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $33.26 | -33.85% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $10.95 | +36.99% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.26 | +147.15% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $35.29 | -20.66% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $2.25 | +2,744.44% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $33.65 | +446.81% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $2.83 | +642.05% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $28.11 | -50.20% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $160 | $4.54 | +3,425.39% | 2 | Dec 15, 2021 |
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $35.58
Upside: -15.68%
Rhythm Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $157 → $139
Current: $109.09
Upside: +27.42%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $20.83
Upside: +15.22%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.18
Upside: -14.89%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $33.26
Upside: -33.85%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $10.95
Upside: +36.99%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.26
Upside: +147.15%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $35.29
Upside: -20.66%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $2.25
Upside: +2,744.44%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $33.65
Upside: +446.81%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $2.83
Upside: +642.05%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $28.11
Upside: -50.20%
Dec 15, 2021
Initiates: Neutral
Price Target: $160
Current: $4.54
Upside: +3,425.39%